Previously treated cases tested for RR-/MDR-TB (%) in Algeria
Algeria: Previously treated cases tested for RR-/MDR-TB was 8.2% in 2023. ◆ Volatile
Latest (2023)
8.2%
Change on year
down 65.8%
World rank
168th
of 180 countries
All-time high
100.0%
in 2017
All-time low
3.6%
in 2018
Years of data
10
2005–2023
Previously treated cases tested for RR-/MDR-TB in Algeria, 2005–2023
Source: World Health Organization, Global Health Observatory.
Analysis
In 2023, previously treated cases tested for rr-/mdr-tb in Algeria stood at 8.2%.
That represents a change of down 65.8% on the previous year and down 74.4% over ten years.
Over the whole period, previously treated cases tested for rr-/mdr-tb in Algeria peaked at 100.0% in 2017 and was at its lowest, 3.6%, in 2018.
That places Algeria 168th out of 180 countries with data for 2023, putting it in the bottom quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Previously treated cases tested for RR-/MDR-TB in Algeria, year by year
| Year | Value | Change |
|---|---|---|
| 2005 | 23.0% | — |
| 2014 | 32.0% | +39.1% |
| 2015 | 42.0% | +31.2% |
| 2016 | 12.0% | -71.4% |
| 2017 | 100.0% | +733.3% |
| 2018 | 3.6% | -96.4% |
| 2019 | 41.0% | +1038.9% |
| 2020 | 30.0% | -26.8% |
| 2022 | 24.0% | -20.0% |
| 2023 | 8.2% | -65.8% |
Algeria compared with similar countries
- Algeria's 8.2% is below the median for upper middle income countries, which is 92.0%, 9% of the median. (52 countries reporting)
- Algeria's 8.2% is below the median for Middle East, North Africa, Afghanistan & Pakistan, which is 90.5%, 9% of the median. (20 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 23.0% | 23.0% | 23.0% | 1 |
| 2010s | 38.4% | 3.6% | 100.0% | 6 |
| 2020s | 20.7% | 8.2% | 30.0% | 3 |
Countries ranked near Algeria
- 165 Cape Verde 20.0% compare
- 166 Djibouti 17.0% compare
- 167 Solomon Islands 9.1% compare
- 169 North Korea 5.1% compare
- 170 France 4.2% compare
- 171 Gabon 3.7% compare
More health data for Algeria
- Un projection of annual infant deaths, annual growth rate -1.82 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5437 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 943.1 deaths per 1,000 people (2090)
- Number of infants who die before age 1 1,455 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.77 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0465 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is previously treated cases tested for rr-/mdr-tb in Algeria?
- Previously treated cases tested for rr-/mdr-tb in Algeria was 8.2% in 2023, according to World Health Organization, Global Health Observatory.
- What is the highest previously treated cases tested for rr-/mdr-tb recorded in Algeria?
- The highest recorded value was 100.0% in 2017.
- What is the lowest previously treated cases tested for rr-/mdr-tb recorded in Algeria?
- The lowest recorded value was 3.6% in 2018.
- How does Algeria rank for previously treated cases tested for rr-/mdr-tb?
- Algeria ranks 168th out of 180 countries with data for 2023.
- Is previously treated cases tested for rr-/mdr-tb rising or falling in Algeria?
- Over the last ten years it is down 74.4%. The long-run trend across the full record is volatile.
- Where does this Algeria data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Previously treated cases tested for RR-/MDR-TB (%). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 10 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).